Description

Capreomycin Iia is a cyclic peptide antibiotic belonging to the capreomycin complex, a second-line therapeutic agent for the treatment of multidrug-resistant tuberculosis (MDR-TB). Its primary value lies in its targeted antibacterial activity against Mycobacterium tuberculosis, particularly strains resistant to first-line drugs like isoniazid and rifampin. This makes it a critical component in the pharmaceutical supply chain for manufacturers of anti-tuberculosis medications, research institutions developing novel therapeutics, and clinical laboratories. The compound is identified by CAS NO 62639-89-8.

Application

• Pharmaceutical Active Ingredient (API): Core component in the formulation of injectable second-line anti-tuberculosis drugs.
• Drug Discovery & Research: Used as a reference standard and building block in microbiological and pharmacological research for novel anti-mycobacterial agents.
• Clinical Diagnostics: Employed in in vitro susceptibility testing to determine the resistance profile of TB patient isolates.
• Veterinary Medicine: Potential application in treating mycobacterial infections in animals, subject to regional regulatory approvals.
• Biochemical Research: Study of peptide antibiotics' mechanism of action, specifically inhibition of bacterial protein synthesis.

Basic Information

Product Name	Capreomycin Iia
CAS No.	62639-89-8
Molecular Formula	C25H44N14O8
Molecular Weight	668.71 g/mol
Synonyms	Capreomycin IA; Capreomycin I A; Capastat Sulfate Component IA; (S)-4,6-Diamino-N-[[(2S,3R,4R,5R)-5-amino-2-[[(2S,3S,6S)-3-amino-6-[[(1R)-1-[[(4S,7R,10S,13S,16R,19S,22S,25S,28S,31S)-7,13,19,25,31-pentakis(2-aminoethyl)-4,10,16,22,28-pentamethyl-3,6,9,12,15,18,21,24,27,30-decaoxodotriacontahydro-1H,2H-dipyrrolo[2,1-i:1',2'-l'][1,4,7,10,13,16,19,22,25,28]decaazacyclodotriacontin-2-yl]carbonyl]ethyl]carbamoyl]oxan-2-yl]carbamoyl]-3,4-dihydroxyoxolan-2-yl]methyl]-6-oxohexane-1,3-diyldicarbamic acid
EINECS	Contact for details

Quality Control

Our Capreomycin Iia is manufactured and tested under strict quality management systems. Each batch is subjected to comprehensive analytical testing, including HPLC for purity and identity confirmation, to ensure it meets high-grade pharmaceutical standards. A detailed Certificate of Analysis (COA) is provided with each shipment, documenting compliance with agreed specifications. We support compliance with cGMP, ICH Q7, and other relevant pharmacopeial guidelines (e.g., USP monographs) for active pharmaceutical ingredients.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). This product is hygroscopic (moisture-sensitive) and must be kept in a dry environment to prevent degradation. For long-term storage, consider desiccants or inert atmosphere packaging.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to reference spectrum
Identification (HPLC)	Retention time corresponds to reference standard
Assay (HPLC)	≥ 95.0% (on anhydrous basis)
Water Content (KF)	≤ 5.0%
Residue on Ignition	≤ 1.0%
Related Substances (HPLC)	Total impurities ≤ 3.0% Any single impurity ≤ 1.0%
Microbial Limits	Meets Ph. Eur. 2.6.12/2.6.13 or USP <61>/<62>

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.